Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;474(11):1123-1132.
doi: 10.1007/s00424-022-02751-2. Epub 2022 Sep 27.

hPSC gene editing for cardiac disease therapy

Amina Saleem  1 , Muhammad Khawar Abbas  2 , Yongming Wang  3   4 , Feng Lan  5   6   7
Affiliations
Review

hPSC gene editing for cardiac disease therapy

Amina Saleem et al. Pflugers Arch. 2022 Nov.

Abstract

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. However, the lack of human cardiomyocytes with proper genetic backgrounds limits the study of disease mechanisms. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have significantly advanced the study of these conditions. Moreover, hPSC-CMs made it easy to study CVDs using genome-editing techniques. This article discusses the applications of these techniques in hPSC for studying CVDs. Recently, several genome-editing systems have been used to modify hPSCs, including zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeat-associated protein 9 (CRISPR/Cas9). We focused on the recent advancement of genome editing in hPSCs, which dramatically improved the efficiency of the cell-based mechanism study and therapy for cardiac diseases.

Keywords: CRISPR/Cas9; Cardiovascular disease; Genome editing; TALEN; ZFN; hiPSC.

PubMed Disclaimer

References

    1. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576:149–157. https://doi.org/10.1038/s41586-019-1711-4 - DOI - PubMed - PMC
    1. Bultmann S, Morbitzer R, Schmidt CS, Thanisch K, Spada F, Elsaesser J, Lahaye T, Leonhardt H (2012) Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 40:5368–5377. https://doi.org/10.1093/nar/gks199 - DOI - PubMed - PMC
    1. Chadwick AC, Musunuru K (2017) Genome editing for the study of cardiovascular diseases. Curr Cardiol Rep 19:22. https://doi.org/10.1007/s11886-017-0830-5 - DOI - PubMed - PMC
    1. Chang L, Zhang J, Tseng YH, Xie CQ, Ilany J, Brüning JC, Sun Z, Zhu X, Cui T, Youker KA, Yang Q, Day SM, Kahn CR, Chen YE (2007) Rad GTPase deficiency leads to cardiac hypertrophy. Circulation 116(25):2976–2983. https://doi.org/10.1161/CIRCULATIONAHA.107.707257 - DOI - PubMed - PMC
    1. Christidi E, Huang HM, Brunham LR (2018) CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: applications for cardiovascular disease modeling and cardiotoxicity screening. Drug Discov Today Technol 28:13–21. https://doi.org/10.1016/j.ddtec.2018.06.002 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources